EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
-5.95%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$5.24B
AUM Growth
-$312M
(-5.6%)
Cap. Flow
+$113M
Cap. Flow
% of AUM
2.16%
Top 10 Holdings %
Top 10 Hldgs %
19.63%
Holding
944
New
50
Increased
219
Reduced
167
Closed
31
Top Buys
| 1 |
Pfizer
PFE
|
+$26.7M |
| 2 |
Sunrun
RUN
|
+$20.2M |
| 3 |
HMHC
Houghton Mifflin Harcourt Company
HMHC
|
+$19.3M |
| 4 |
Danaher
DHR
|
+$14.7M |
| 5 |
NOVA
Sunnova Energy
NOVA
|
+$13.5M |
Top Sells
| 1 |
Foot Locker
FL
|
+$42.5M |
| 2 |
Walmart
WMT
|
+$16M |
| 3 |
Masimo
MASI
|
+$15.8M |
| 4 |
Enovis
ENOV
|
+$14.8M |
| 5 |
JPMorgan Chase
JPM
|
+$14.1M |
Sector Composition
| 1 | Technology | 31.7% |
| 2 | Healthcare | 18.75% |
| 3 | Consumer Discretionary | 11.87% |
| 4 | Financials | 9.73% |
| 5 | Industrials | 7.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
W.R. Berkley
WRB
$27.5B
| $302K | 0.01% |
6,750
| – | – |
|
477
Markel Group
MKL
$24.4B
| $299K | 0.01% |
200
| – | – |
|
478
Blue Owl Capital
OWL
$11.7B
| $297K | 0.01% |
23,460
| – | – |
|
479
American Financial Group
AFG
$11.5B
| $295K | 0.01% |
2,000
| – | – |
|
480
Allogene Therapeutics
ALLO
$253M
| $294K | 0.01% |
31,400
-9,400
| -23% | -$87.9K |
|
481
Editas Medicine
EDIT
$251M
| $293K | 0.01% |
+15,000
| New | +$293K |
|
482
Lyell Immunopharma
LYEL
$250M
| $289K | 0.01% |
+2,700
| New | +$289K |
|
483
Fair Isaac
FICO
$36.9B
| $288K | 0.01% |
600
| – | – |
|
484
CDW
CDW
$22B
| $282K | 0.01% |
1,575
-9,481
| -86% | -$1.7M |
|
485
Alector
ALEC
$279M
| $276K | 0.01% |
+19,000
| New | +$276K |
|
|
VERV
486
DELISTED
Verve Therapeutics
VERV
| $274K | 0.01% |
+11,300
| New | +$274K |
|
487
Sealed Air
SEE
$4.86B
| $273K | 0.01% |
4,000
-1,500
| -27% | -$102K |
|
488
Rocket Pharmaceuticals
RCKT
$352M
| $266K | 0.01% |
16,700
| – | – |
|
|
PSTH
489
DELISTED
Pershing Square Tontine Holdings, Ltd.
PSTH
| $264K | 0.01% |
13,250
| – | – |
|
490
Nektar Therapeutics
NKTR
$843M
| $261K | 0.01% |
3,120
| – | – |
|
491
C4 Therapeutics
CCCC
$193M
| $258K | ﹤0.01% |
+10,700
| New | +$258K |
|
492
Recursion Pharmaceuticals
RXRX
$2.02B
| $239K | ﹤0.01% |
+33,500
| New | +$239K |
|
493
PVH
PVH
$4.07B
| $232K | ﹤0.01% |
2,800
-200
| -7% | -$16.5K |
|
494
Sangamo Therapeutics
SGMO
$158M
| $225K | ﹤0.01% |
38,000
| – | – |
|
495
Erasca
ERAS
$440M
| $225K | ﹤0.01% |
+25,000
| New | +$225K |
|
|
IMGN
496
DELISTED
Immunogen Inc
IMGN
| $223K | ﹤0.01% |
+47,000
| New | +$223K |
|
497
Anavex Life Sciences
AVXL
$803M
| $221K | ﹤0.01% |
+18,000
| New | +$221K |
|
498
West Fraser Timber
WFG
$6.01B
| $216K | ﹤0.01% |
2,500
-850
| -25% | -$73.6K |
|
499
W.W. Grainger
GWW
$47.7B
| $209K | ﹤0.01% |
+405
| New | +$209K |
|
500
Arcutis Biotherapeutics
ARQT
$2.08B
| $208K | ﹤0.01% |
11,100
| – | – |
|